# SHR-A2009

Source: https://onco.cc/drugs/shr-a2009/  
OnCo record `shr-a2009` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SHR-A2009 is an experimental investigational agent whose form is not stated in the registry from Shanghai Hengrui Pharmaceutical in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.

## Summary

SHR-A2009 is an investigational agent whose form is not stated in the registry developed by Shanghai Hengrui Pharmaceutical and Suzhou Suncadia Biopharmaceuticals. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: SHR-A2009 monotherapy ，SHR-A2009 will be administered intravenously. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06671379 (A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC), in non-small-cell lung cancer. The largest, NCT06671379, plans to enrol 498 participants (actual) with primary completion expected 2026-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record
- Mechanism: Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.

## Sources

- ClinicalTrials.gov: trials of SHR-A2009: https://clinicaltrials.gov/search?intr=SHR-A2009

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)
- trials: [A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06474455/), [A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC](https://onco.cc/trials/nct07183189/), [A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC](https://onco.cc/trials/nct06671379/), [Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer](https://onco.cc/trials/nct06222879/)

---
JSON: https://onco.cc/api/v1/entities/shr-a2009.json